Amgen (AMGN) has initiated two phase 3 trials for its obesity drug MariTide, the company's Head of Research and Development, Jay Bradner, said Wednesday at an investor conference.

One of the trials is in people with obesity or overweight without type 2 diabetes, and is expected to enroll 3,500 people, Bradner said. The second trial is in people with obesity or overweight who have type 2 diabetes, with Amgen intending to enroll 999 patients, he added.

The studies will test different dose levels, starting at a lower dose. Bradner said the primary endpoint is the change in baseline body weight at 72 weeks.

Price: 313.79, Change: +1.60, Percent Change: +0.51